QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

JAZZ

QT61Jazz Pharmaceuticals plc
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
224.66
-2.27-1.00%
OverviewShort InterestFilings
JAZZQT61Jazz Pharmaceuticals plc·NASDAQ
OverviewShort InterestFilings
224.66-1.00%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E476.28EPS (ttm)
0.11
Insider Own4.00%
Shs Outstand62.82M
Perf Week-4.87%
Market Cap14.26BForward P/E8.72EPS next Y25.75Insider Trans0.06%Shs Float-Perf Month-5.39%
Enterprise Value17.83BPEG-EPS next Q6.18Inst Own-Short Float-Perf Quarter23.58%
Income29.94MP/S3.21EPS this Y22959.78%Inst Trans-Short Ratio-Perf Half Y32.36%
Sales4.44BP/B3.10EPS next Y1.52%ROA0.25%Short Interest-Perf YTD32.15%
Book/sh72.14P/C10.53EPS next 5Y7.40%ROE0.71%52W High243.32 -7.67%Perf Year109.86%
Cash/sh45.75P/FCF11.44EPS past 3/5Y-ROIC-0.62%52W Low105.00 113.96%Perf 3Y-
Dividend Est.-EV/EBITDA32.76Sales past 3/5Y5.27% 12.54%Gross Margin84.12%Volatility1.60% 1.90%Perf 5Y-
Dividend TTM-EV/Sales4.02EPS Y/Y TTM48.67%Oper. Margin11.13%ATR (14)6.66Perf 10Y-
Dividend Ex-Date-Quick Ratio1.85Sales Y/Y TTM9.09%Profit Margin0.66%RSI (14)45.78Recom2.11
Dividend Gr. 3/5Y-Current Ratio2.04EPS Q/Q277.38%SMA20-3.60%Beta0.46Target Price257.44
Payout0.00%Debt/Eq1.20Sales Q/Q19.04%SMA502.00%Rel Volume1.99Prev Close226.93
Employees2,800LT Debt/Eq1.01EarningsAug 04SMA20028.34%Avg Volume959.15KPrice224.66
IPO DateJun 01, 2007Option/ShortYes / YesEPS/Sales Surpr.36.64% 9.19%Net Debt/EBITDA6.57Volume1,906,763Change-1.00%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-09-26ReiteratedTruist Financial$205 → $256
May-27-26ReiteratedBarclaysOverweight$234 → $253
May-22-26ReiteratedPiper SandlerOverweight$219 → $301
May-21-26InitiatedBernsteinMarket Perform$175 → $229
May-19-26UpgradeUBSNeutral → Buy$188 → $307
May-07-26ReiteratedMorgan StanleyOverweight$226 → $245
May-06-26ReiteratedRaymond James$227 → $239
May-06-26ReiteratedRobert W. Baird$209 → $252
May-06-26ReiteratedBarclaysOverweight$225 → $234
Apr-20-26ReiteratedBarclaysOverweight$224 → $225
Latest News
Jun-18-26
Jun-18-2602:29PM
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor TherapiesYahoo
12:35PM
Cannabis Stocks Split into Two Camps: Profitable Operators vs. High-Growth SpeculationChartMill
10:33AM
Jazz and AbCellera sign deal for T-cell engagers in solid tumoursYahoo
Jun-17-26
Jun-17-2601:15PM
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Fed Rates AnnouncementYahoo
12:54PM
Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera CollaborationBenzinga
12:50PM
Jazz Pharmaceuticals and AbCellera Partner on Antibody Programs for Solid TumorsYahoo
11:00AM
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific AntibodiesYahoo
07:11AM
Jazz Pharma And AbCellera Announce Preclinical Research Collaboration, Option And License Agreement To Discover, Develop Next-Gen T-Cell Engaging Multispecific AntibodiesBenzinga
Jun-16-26
Jun-16-2608:05PM
Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic HypersomniaYahoo
04:07PM
Jazz Pharma Announces 11 Late-Breaking Presentations At SLEEP 2026, Including New Research Showcasing Comprehensive Treatment Outcomes Of Xywav Oral Solution In Patients With Narcolepsy And IHBenzinga
Jun-15-26
Jun-15-2609:48PM
Jazz Pharmaceuticals (JAZZ): Buy, Sell, or Hold Post Q1 Earnings?Yahoo
04:12PM
Pharmaceuticals Stocks Q1 Recap: Benchmarking Jazz Pharmaceuticals (NASDAQ:JAZZ)Yahoo
Jun-12-26
Jun-12-2607:40PM
Sector Update: Healthcare Stocks Softer Late AfternoonYahoo
12:00PM
Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung CancerYahoo
08:05AM
Jazz Pharmaceuticals Announces Phase 3 LAGOON Study Of Zepzelca In Participants With Relapsed Metastatic Small Cell Lung Cancer Failed To Meet Primary Endpoint Of Overall SurvivalBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue4,4394,2684,069
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A705503446
Gross Profit3,7333,7643,623
Selling, General and Administrative Excl. Other1,6481,8091,385
Research and Development736783884
Other Operating Expense856948638
Operating Income495224717
Interest Expense204195238
Unusual Expense
———
Non-Operating Income (Expense)509658-145
Net Income Before Taxes-220-629469
Income Taxes-248-272-91
Consolidated Net Income29-356560
Net Income From Continuing Operations29-356560
Net Income29-356560
EPS (Recurring)0.41-5.849.06
EPS (Basic, Before Extraordinaries)0.41-5.849.06
EPS (Diluted)0.11-5.848.65
EBITDA5451081,522
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
2,042.36——
Price To Sales Ratio3.142.43—
Gross Margin84.1088.1989.04
Operating Margin11.155.2517.62
Net Margin0.65-8.3413.76
Shares Outstanding626162
Market Capitalization13,92910,370—
Operating Lease Expense
———
Insider Trading Volume
$242.75$218.27$193.79$169.31$144.83● Close Price0.00M5.20M10.41M15.61M20.81MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Smith Mark DouglasDirectorJun 15 '26Sale230.551,157266,7469,680Jun 17 12:00 AM
Patil Neena MEVP & Chief Legal OfficerJun 10 '26Sale231.831,200278,19651,549Jun 12 12:00 AM
Mulligan SeamusDirectorMay 28 '26Option Exercise138.086,830943,0861,183,028Jun 01 12:00 AM
Patil Neena MEVP & Chief Legal OfficerMay 28 '26Sale236.971,192282,46852,626Jun 01 12:00 AM
Pearce SamanthaEVP, Chief Commercial OfficerMay 28 '26Sale235.416,9071,625,97750,272Jun 01 12:00 AM
Pearce SamanthaEVP, Chief Commercial OfficerMay 28 '26Option Exercise109.4513,8141,511,94257,179Jun 01 12:00 AM
Winningham Rick EDirectorMay 22 '26Sale241.572,741662,1439,567May 27 12:00 AM
Winningham Rick EDirectorMay 22 '26Option Exercise138.086,830943,08612,308May 27 12:00 AM
McSharry Heather AnnDirectorMay 22 '26Sale241.002,000482,00018,449May 27 12:00 AM
COZADD BRUCE CDirectorMay 01 '26Sale203.336,0001,219,980378,682May 05 12:00 AM
COZADD BRUCE CDirectorApr 01 '26Sale190.506,0001,143,011384,682Apr 03 12:00 AM
Carr PatriciaSVP, Chief Accounting OfficerMar 09 '26Sale182.941,287235,4446,512Mar 09 12:00 AM
COZADD BRUCE CDirectorMar 03 '26Sale186.446,0001,118,613405,796Mar 04 12:00 AM
RIEDEL NORBERT GDirectorFeb 27 '26Option Exercise138.086,830943,08610,439Mar 02 12:00 AM
RIEDEL NORBERT GDirectorFeb 27 '26Sale192.003,415655,6807,024Mar 02 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR